Study to test solanezumab's potential in preventing Alzheimer's

01/20/2013 | Washington Times, The

Dr. Reisa Sperling, director of the Alzheimer's disease center at Brigham and Women's Hospital in Boston, will be heading a study that will test an experimental drug from Eli Lilly & Co. called solanezumab. The study, to include 1,000 people with plaque buildup but no signs of dementia, will test whether the drug can prevent the development of Alzheimer's when administered before symptoms manifest. Researchers are also paying close attention to whether the drug can at least hinder the speed of cognitive degeneration.

View Full Article in:

Washington Times, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA